Specific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults
Completed
- Conditions
- MenC conjugate vaccination, Memory B cells, infectious diseases, meningitis
- Registration Number
- NL-OMON27223
- Lead Sponsor
- ational Institute for Public Health and the Environment (RIVM)Laboratory for Vaccine Preventable Diseases (LTR)Antonie van Leeuwenhoeklaan 93721 MA Bilthoven
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 21
Inclusion Criteria
1. Good general health;
2. Provision of written informed consent;
Exclusion Criteria
1. Severe acute (infectious) illness of fever (>38.5°C) within 2 weeks before vaccination;
2. Present evidence of serious disease(s) demanding medical treatment that might interfere the results of the study;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - How long does B-cell memory persist after a single conjugate MenC vaccination in adults and which cells are involved?
- Secondary Outcome Measures
Name Time Method - How long do serum SBA titers persist in time after a single vaccination with the conjugate MenC vaccine?<br /><br>- Despite decline of antibody concentrations in the years after vaccination, do memory B-cells persist? <br /><br>- Antibody kinetics, it is important to follow the rise of antibody titers after vaccination: <br /><br>o How long will it take before serum IgG antibodies are detectable and/or rise after primary- or booster vaccination?<br /><br>o What is the avidity of serum IgG antibodies compared to the primary and booster vaccination?<br /><br>- In what time period after primary vaccination with MenC are memory B-cells formed and how rapidly do memory B-cells expand after booster vaccination?<br /><br>- Are there differences (antibody titer levels, IgG subclass distribution and serum antibody avidity) in booster responses between a booster vaccination using the conjugate MenC vaccine or plain serogroup C capsular polysaccharide .